Please enable JavaScript to continue using this application.

Compare $CADL vs $SLDB | Chartloom

Compare

$CADL vs $SLDB

Candel Therapeutics Inc · Solid Biosciences Inc

CADL

Candel Therapeutics Inc

SLDB

Solid Biosciences Inc

Compare $CADL vs $SLDB

Comparing Candel Therapeutics Inc and Solid Biosciences Inc

CADLCandel Therapeutics Inc

SLDBSolid Biosciences Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

SLDBSolid Biosciences Inc

Market cap

$676M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

26.1%

52W performance

8.9%

FCF yield

-27.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

SLDB

Detailed metrics comparison

CADL

Candel Therapeutics Inc

SLDB

Solid Biosciences Inc

Market Cap

CADL$728M

SLDB$676M

Enterprise Value

CADL$575M

SLDB$517M

Price

CADL$9.94

SLDB$6.87

P/E Ratio

CADLN/A

SLDBN/A

P/S Ratio

CADL6,281.93x

SLDB49.66x

EV/Sales

CADL5,042.14x

SLDB38.88x

EV/EBITDA

CADL0.00x

SLDB0.00x

P/B Ratio

CADL6.18x

SLDB1.96x

P/FCF Ratio

CADLN/A

SLDBN/A

EV/FCF

CADL-10.02x

SLDB-2.75x

PEG Ratio

CADLN/A

SLDBN/A

Forward P/E (NTM)

CADLN/A

SLDBN/A

Forward P/S (NTM)

CADLN/A

SLDBN/A

Revenue (TTM)

CADL$0

SLDB$0

Revenue Growth (YoY)

CADLN/A

SLDBN/A

Forward Rev Growth

CADL371.1%

SLDB822.7%

Gross Margin (TTM)

CADL0.0%

SLDB0.0%

Operating Margin (TTM)

CADL0.0%

SLDB0.0%

EBITDA Margin (TTM)

CADL0.0%

SLDB0.0%

Net Margin (TTM)

CADL0.0%

SLDB0.0%

FCF Margin (TTM)

CADLN/A

SLDBN/A

Net Income (TTM)

CADL$-89M

SLDB$-207M

FCF (TTM)

CADL$-57M

SLDB$-188M

EPS (TTM)

CADL-$1.19

SLDB-$1.44

ROE (TTM)

CADL-8938.0%

SLDB-7228.0%

ROA (TTM)

CADL-5631.0%

SLDB-6137.0%

ROIC (TTM)

CADL-6512.0%

SLDB-7226.0%

Cash

CADL$202M

SLDB$159M

Debt

CADL$48M

SLDB$0

Net Cash/Debt

CADL$154M

SLDB$159M

Current Ratio (TTM)

CADL16.09x

SLDB13.82x

Quick Ratio (TTM)

CADL15.89x

SLDB13.24x

Debt/Equity (TTM)

CADL0.38x

SLDB0.00x

Debt/Assets (TTM)

CADL0.0%

SLDB0.0%

Interest Coverage (TTM)

CADLN/A

SLDBN/A

Net Debt/EBITDA (TTM)

CADL0.00x

SLDB0.00x

Beta

CADL-0.28

SLDB2.60

52W Performance

CADL57.8%

SLDB8.9%

YTD Performance

CADL82.7%

SLDB26.1%

% from 52W High

CADL-29.0%

SLDB-40.0%

% from 52W Low

CADL128.5%

SLDB81.3%

Asset Turnover (TTM)

CADL0.00x

SLDB0.07x

FCF Yield (TTM)

CADL-7.9%

SLDB-27.8%

Earnings Yield (TTM)

CADL-12.2%

SLDB-30.6%

Dividend Yield (TTM)

CADLN/A

SLDBN/A

Rule of 40

CADL0.0

SLDB0.0

EV/GP/RG

CADLN/A

SLDBN/A

Ticker research

View CADL research View SLDB research

Metric	CADL Candel Therapeutics Inc	SLDB Solid Biosciences Inc
Market & Valuation
Market Cap	$728M	$676M
Enterprise Value	$575M	$517M
Price	$9.94	$6.87
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	49.66x
EV/Sales	5,042.14x	38.88x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.96x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-2.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	371.1%	822.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-89M	$-207M
FCF (TTM)	$-57M	$-188M
EPS (TTM)	-$1.19	-$1.44
ROE (TTM)	-8938.0%	-7228.0%
ROA (TTM)	-5631.0%	-6137.0%
ROIC (TTM)	-6512.0%	-7226.0%
Financial Health
Cash	$202M	$159M
Debt	$48M	$0
Net Cash/Debt	$154M	$159M
Current Ratio (TTM)	16.09x	13.82x
Quick Ratio (TTM)	15.89x	13.24x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.60
52W Performance	57.8%	8.9%
YTD Performance	82.7%	26.1%
% from 52W High	-29.0%	-40.0%
% from 52W Low	128.5%	81.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-7.9%	-27.8%
Earnings Yield (TTM)	-12.2%	-30.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View SLDB research

Valuation

P/S Ratio

SLDB

49.66x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

SLDB

-2.75x

Growth & revenue

Forward Revenue Growth

SLDB

822.7%

CADL

371.1%

Profitability & performance

Gross Margin

CADL

0.0%

SLDB

0.0%

ROE

SLDB

-7228.0%

CADL

-8938.0%

FCF Yield %

CADL

-7.9%

SLDB

-27.8%

52-Week Performance

CADL

57.8%

SLDB

8.9%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

SLDB

Solid Biosciences Inc

Market Cap

CADL$728M

SLDB$676M

Enterprise Value

CADL$575M

SLDB$517M

Price

CADL$9.94

SLDB$6.87

P/E Ratio

CADLN/A

SLDBN/A

P/S Ratio

CADL6,281.93x

SLDB49.66x

EV/Sales

CADL5,042.14x

SLDB38.88x

EV/EBITDA

CADL0.00x

SLDB0.00x

P/B Ratio

CADL6.18x

SLDB1.96x

P/FCF Ratio

CADLN/A

SLDBN/A

EV/FCF

CADL-10.02x

SLDB-2.75x

PEG Ratio

CADLN/A

SLDBN/A

Forward P/E (NTM)

CADLN/A

SLDBN/A

Forward P/S (NTM)

CADLN/A

SLDBN/A

Revenue (TTM)

CADL$0

SLDB$0

Revenue Growth (YoY)

CADLN/A

SLDBN/A

Forward Rev Growth

CADL371.1%

SLDB822.7%

Gross Margin (TTM)

CADL0.0%

SLDB0.0%

Operating Margin (TTM)

CADL0.0%

SLDB0.0%

EBITDA Margin (TTM)

CADL0.0%

SLDB0.0%

Net Margin (TTM)

CADL0.0%

SLDB0.0%

FCF Margin (TTM)

CADLN/A

SLDBN/A

Net Income (TTM)

CADL$-89M

SLDB$-207M

FCF (TTM)

CADL$-57M

SLDB$-188M

EPS (TTM)

CADL-$1.19

SLDB-$1.44

ROE (TTM)

CADL-8938.0%

SLDB-7228.0%

ROA (TTM)

CADL-5631.0%

SLDB-6137.0%

ROIC (TTM)

CADL-6512.0%

SLDB-7226.0%

Cash

CADL$202M

SLDB$159M

Debt

CADL$48M

SLDB$0

Net Cash/Debt

CADL$154M

SLDB$159M

Current Ratio (TTM)

CADL16.09x

SLDB13.82x

Quick Ratio (TTM)

CADL15.89x

SLDB13.24x

Debt/Equity (TTM)

CADL0.38x

SLDB0.00x

Debt/Assets (TTM)

CADL0.0%

SLDB0.0%

Interest Coverage (TTM)

CADLN/A

SLDBN/A

Net Debt/EBITDA (TTM)

CADL0.00x

SLDB0.00x

Beta

CADL-0.28

SLDB2.60

52W Performance

CADL57.8%

SLDB8.9%

YTD Performance

CADL82.7%

SLDB26.1%

% from 52W High

CADL-29.0%

SLDB-40.0%

% from 52W Low

CADL128.5%

SLDB81.3%

Asset Turnover (TTM)

CADL0.00x

SLDB0.07x

FCF Yield (TTM)

CADL-7.9%

SLDB-27.8%

Earnings Yield (TTM)

CADL-12.2%

SLDB-30.6%

Dividend Yield (TTM)

CADLN/A

SLDBN/A

Rule of 40

CADL0.0

SLDB0.0

EV/GP/RG

CADLN/A

SLDBN/A

Ticker research

View CADL research View SLDB research

Metric	CADL Candel Therapeutics Inc	SLDB Solid Biosciences Inc
Market & Valuation
Market Cap	$728M	$676M
Enterprise Value	$575M	$517M
Price	$9.94	$6.87
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	49.66x
EV/Sales	5,042.14x	38.88x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.96x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-2.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	371.1%	822.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-89M	$-207M
FCF (TTM)	$-57M	$-188M
EPS (TTM)	-$1.19	-$1.44
ROE (TTM)	-8938.0%	-7228.0%
ROA (TTM)	-5631.0%	-6137.0%
ROIC (TTM)	-6512.0%	-7226.0%
Financial Health
Cash	$202M	$159M
Debt	$48M	$0
Net Cash/Debt	$154M	$159M
Current Ratio (TTM)	16.09x	13.82x
Quick Ratio (TTM)	15.89x	13.24x
Debt/Equity (TTM)	0.38x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.60
52W Performance	57.8%	8.9%
YTD Performance	82.7%	26.1%
% from 52W High	-29.0%	-40.0%
% from 52W Low	128.5%	81.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.07x
FCF Yield (TTM)	-7.9%	-27.8%
Earnings Yield (TTM)	-12.2%	-30.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View SLDB research